Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
April 16, 2024Johnson & Johnson Releases First Quarter 2024 Results: Q1 2024 SalesReached 21.383 billion US dollars, year-on-yearIncrease by 2.3%; R&D expenses of $3.542 billion, increased by 2.5% year-on-year.
From the perspective of specific business divisions,Q1 2024 Innovative Drug Business Revenue 135.$6.2 billion, a year-on-year increase of 1.1%. Medical device sector revenue reached $7.8 billion..$2.1 billion, a year-on-year increase of 4.5%.
From a regional perspective,U.S. Business is the Pillar of Johnson & Johnson. Q1 2024 Revenue was $11.62 Billion, a Year-on-Year Increase of 7.8%. International Business Outside the U.S. Achieved an Annual Revenue of $9.763 Billion, a Year-on-Year Increase of 3.4%.
Johnson & Johnson's innovative pharmaceuticals business mainly focuses on several major fields: autoimmune diseases, oncology, neuroscience, infectious diseases, pulmonary hypertension, cardiovascular and metabolic diseases.In the innovative drug business,The main factors driving growth are:Immunotherapy ProductsTREMFYA (Guselkumab), SIMPONI/SIMPONI ARIA (Golimumab),STELARA (Ustekinumab) ；Anti-tumor ProductsDARZALEX (Daratumumab), ERLEADA (Apalutamide)TECVAYLI (Talquetamab)CARVYKTI (Ciltacabtagene Autoleucel);Pulmonary Arterial Hypertension Treatment DrugsOpsumit (Macitentan)AndUPTRAVI (selexipag).
In the field of oncology，The sales performance of Carvykti, the BCMA CAR-T therapy developed through the collaboration between Johnson & Johnson and Legend Biotech, is a major highlight.Carvykti 2024 Q1 Total Sales Reached $157 Million (Approx. 1.1 Billion Yuan), Surging 118% Year-over-YearExpected to exceed 1 billion US dollars in 2024 (currently only available in the US, EU, and Japan).
Carvykti is a CAR-T cell therapy targeting BCMA, which modifies the patient's own T cells using a transgene for a chimeric antigen receptor to identify and eliminate cells expressing BCMA.April 15, 2024`, the U.S. Food and Drug Administration (FDA) has approved`CarvyktiFor the treatment of patients with relapsed or refractory multiple myeloma,CARVYKTI®It is the first and only B-cell maturation antigen (BCMA) targeted therapy approved for second-line treatment of multiple myeloma patients.Moreover, the autoimmune field has gradually become an important pillar for the performance of pharmaceutical giants.，StElara Remains the Main Growth Driver of Johnson & Johnson's Autoimmunity Segment, with Total Sales of $2.451 Billion in Q1 2024, a Year-on-Year Increase of 0.3%. As Stelara’s Core Patent Expires and Biosimilars Enter the European Market, Stelara’s Revenue is Expected to Begin Declining. The Next-Generation Monoclonal Antibody Targeting IL-23 p19, Tremfya, Successfully Takes Over, Achieving $808 Million in Sales in Q1 2024.Johnson & Johnson has long been prepared for the future,Has begun layout in multiple fields such as oncology, infectious diseases, and cardiovascular.Currently, there are 13 drugs in the NDA stage, 39 drugs in Phase 3 clinical trials, 20 drugs in Phase 2 clinical trials, and 23 drugs in Phase 1 clinical trials.
Johnson & Johnson also raised its full-year operational sales growth forecast to 5.5%-6% (US$887 billion to US$891 billion) from the previous expectation of 5%-6% (US$882 billion to US$890 billion).
In 2024, Johnson & Johnson will achieve multiple milestones in regulatory approvals for new drugs/indications, submission of marketing applications, and the readout of clinical data.
References:Official Website
